Pexidartinib

吡昔替尼

Report date: 2026/04/30 20:00:20
NMEFirst In Class

Base Information

Drug NamePexidartinib
Drug Alias NamePexidartinib Hydrochloride培达替尼盐酸吡昔替尼TuralioPLX-3397
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionStem cell growth factor receptor inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsColony stimulating factor 1 receptor inhibitors
TargetsStem cell growth factor receptorColony stimulating factor 1 receptorTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursArthritis, Rheumatoid +[24] 
Global Approved IndicationsGiant Cell Tumor of Tendon Sheath
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/08/02
Country/TerritoryCanadaUnited StatesTaiwan +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdDaiichi Sankyo IncNational Cancer Institute +[5] 
Inactive CompaniesCatalent Pharma SolutionsDaiichi Sankyo Europe GmbhBarbara Ann Karmanos Cancer Institute +[4] 
Active IndicationsSolid tumoursNeurofibroma, PlexiformSarcoma +[6] 
Inactive IndicationsMetastatic breast cancerArthritis, RheumatoidNeoplasm Metastasis +[18] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG